Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

emicizumab

A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:emicizumab-kxwh
US brand name:Hemlibra
Code name:ACE 910
ACE-910
ACE910
Chemical structure:immunoglobulin G4-kappa, bispecific, anti-(Homo sapiens F9a (activated coagulation factor F9, activated coagulation factor IX) and anti-(Homo sapiens F10 (coagulation factor 10, coagulation factor X)), humanized monoclonal antibody
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search